NCT01854814View on ClinicalTrials.gov

The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients

NACompletedINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

February 28, 2022

Study Completion Date

May 31, 2022

Conditions
IgA Nephropathy
Interventions
DRUG

Mycophenolate mofetil

Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan

DRUG

Losartan

Maximum tolerated labeled dose of Losartan

Trial Locations (3)

510515

Nanfang Hospital Southern Medical University, Guangzhou

518000

The Fourth People's Hospital Shenzhen, Shenzhen

524001

The Institute of Nephrology, Guangdong Medical College, Zhanjiang

All Listed Sponsors
lead

Fan Fan Hou

OTHER

NCT01854814 - The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients | Biotech Hunter | Biotech Hunter